Tvardi Therapeutics reported second quarter 2026 financial results and business updates. The company announced topline healthy volunteer data for its next-generation STAT3 inhibitor TTI-109, confirming improved tolerability and target engagement, and selected ulcerative colitis as the initial indication. R&D expenses decreased to $4.0 million from $5.8 million in the prior year period, while G&A expenses fell to $2.6 million from $3.1 million. The company reported a net loss of $6.5 million compared to a net income of $4.2 million previously, primarily due to the absence of a non-cash gain on convertible notes. Cash and short-term investments stood at $15.8 million as of June 30, 2026, sufficient through Q3 2027. Tvardi Therapeutics is a clinical-stage biopharmaceutical company developing oral small molecule therapies targeting STAT3 for inflammatory and proliferative diseases.

Tvardi Therapeutics announced the selection of ulcerative colitis as the initial disease indication for its next-generation STAT3 inhibitor, TTI-109. This strategic pivot follows a successful Phase 1 healthy volunteer study demonstrating that TTI-109 modulates multiple immune cell populations implicated in UC pathology, including up to 76% reduction in pathogenic Th17 subsets and significant suppression of B cells. The company plans to initiate a clinical trial for TTI-109 in patients with moderate-to-severe ulcerative colitis in 2027, pending Investigational New Drug application clearance and additional funding. Tvardi Therapeutics is a clinical-stage biopharmaceutical company focused on developing oral small molecule therapies targeting STAT3 to treat inflammatory and proliferative diseases.

Tvardi Therapeutics, Inc. amended its Capital on Demand☖ Sales Agreement with JonesTrading Institutional Services LLC to increase its at-the-market offering program by up to $9,689,765 in additional common stock. The company's previous 12-month sales under the following agreement were approximately $11.0 million in gross proceeds. Tvardi Therapeutics, Inc. is a biotechnology company focused on developing therapeutic solutions for cancer.

Tvardi Therapeutics, Inc. issued a press release on July 7, 2026, providing clinical updates on TTI-109, confirming prodrug design, improved tolerability, and pharmacodynamic evidence of STAT3 target engagement. The company also released an updated corporate presentation. Tvardi Therapeutics, Inc. is a biotechnology company focused on developing therapeutic solutions for cancer treatment.